Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.
Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online
The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.
Management and five retina specialists to address commercial readiness
REGENXBIO management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and the commercial readiness of sura-vec in wet AMD.
Five key opinion leaders are scheduled to appear:
- Gaurav Shah, California Pacific Medical Center, Sutter Health
- Arshad Khanani, Sierra Eye Associates
- Lejla Vajzovic, Duke University School of Medicine
- Rahul Khurana, Northern California Retina Vitreous Associates, University of California at San Francisco
- Ramanath Bhandari, Springfield Clinic Eye Institute
Pivotal readout is the next catalyst for the AbbVie-partnered asset
The event precedes the topline results from the two pivotal trials, which the company expects in the fourth quarter of 2026. The company is also developing sura-vec for diabetic retinopathy with AbbVie.
Webcast replay available for about 30 days
An archived replay will be posted in the Investors section of REGENXBIO's website for approximately 30 days after the event.